Manufacturers of Lab PCR Assays

[Linking template=”default” search=” Anti-8-oxo-dG” site=”gentaur.it” classTable=”Gentaur” limit=”66″ start=”1″ linkProductCatalogNumber=”true” showSupplier=”true” showName=”true” showCatalogNumber=”true” showSize=”true” showPrice=”true” showImage=”true” showRequestButton=”true” orderClassName=”Gentaur” orderRequestButtonText=”Gentaur” orderRequestButtonColorText=”rgb(166,77,121)” orderRequestButtonColorBackground=”rgb(217,210,233)” placeholderColorText=”d9d2e9″ placeholderColorBackground=”000000″]

Compare polyclonal lab reagents for research

Suppliers for Lab ELISAs [Linking template=”default” search=”RNA” site=”gentaur.es” header=”h2″ limit=”7″ start=”18″ linkProductCatalogNumber=”false” showSupplier=”true” showName=”true” showCatalogNumber=”true” showSize=”true” showDescription=”true” showImage=”true” linkProductImage=”true”] [Linking template=”default” search=”polyclonal” site=”gentaur.co.uk” header=”h2″ limit=”8″ linkProductSupplierName=”true” showSupplier=”true” showName=”true” showCatalogNumber=”true” showSize=”true” showPrice=”true” showImage=”true”] Our used rec. in Pubmed. [Linking template=”default” search=”rec.” header=”h3″ start=”12″ limit=”5″ linkProductSupplierName=”true” showSupplier=”true” showName=”true” showCatalogNumber=”true” showSize=”true” showPrice=”true” showImage=”true”] Rdi, Antibodies, Elisa kits

Compare Appoptosis lab reagents for research

Suppliers for Lab ELISAs [Linking template=”default” search=”RNA” site=”gentaur.es” header=”h2″ limit=”7″ start=”18″ linkProductCatalogNumber=”false” showSupplier=”true” showName=”true” showCatalogNumber=”true” showSize=”true” showDescription=”true” showImage=”true” linkProductImage=”true”] [Linking template=”default” search=”polyclonal” site=”gentaur.co.uk” header=”h2″ limit=”8″ linkProductSupplierName=”true” showSupplier=”true” showName=”true” showCatalogNumber=”true” showSize=”true” showPrice=”true” showImage=”true”] Our used rec. in Pubmed. [Linking template=”default” search=”rec.” header=”h3″ start=”12″ limit=”5″ linkProductSupplierName=”true” showSupplier=”true” showName=”true” showCatalogNumber=”true” showSize=”true” showPrice=”true” showImage=”true”] Rdi, Antibodies, Elisa kits

Compare Appoptosis lab reagents for research

Suppliers for Lab ELISAs [Linking template=”default” search=”RNA” site=”gentaur.es” header=”h2″ limit=”7″ start=”18″ linkProductCatalogNumber=”false” showSupplier=”true” showName=”true” showCatalogNumber=”true” showSize=”true” showDescription=”true” showImage=”true” linkProductImage=”true”] [Linking template=”default” search=”polyclonal” site=”gentaur.co.uk” header=”h2″ limit=”8″ linkProductSupplierName=”true” showSupplier=”true” showName=”true” showCatalogNumber=”true” showSize=”true” showPrice=”true” showImage=”true”] Our used rec. in Pubmed. [Linking template=”default” search=”rec.” header=”h3″ start=”12″ limit=”5″ linkProductSupplierName=”true” showSupplier=”true” showName=”true” showCatalogNumber=”true” showSize=”true” showPrice=”true” showImage=”true”] Rdi, Antibodies, Elisa kits

Compare monoclonal lab reagents for research

Suppliers for Lab ELISAs [Linking template=”default” search=”RNA” site=”gentaur.es” header=”h2″ limit=”7″ start=”18″ linkProductCatalogNumber=”false” showSupplier=”true” showName=”true” showCatalogNumber=”true” showSize=”true” showDescription=”true” showImage=”true” linkProductImage=”true”] [Linking template=”default” search=”polyclonal” site=”gentaur.co.uk” header=”h2″ limit=”8″ linkProductSupplierName=”true” showSupplier=”true” showName=”true” showCatalogNumber=”true” showSize=”true” showPrice=”true” showImage=”true”] Our used rec. in Pubmed. [Linking template=”default” search=”rec.” header=”h3″ start=”12″ limit=”5″ linkProductSupplierName=”true” showSupplier=”true” showName=”true” showCatalogNumber=”true” showSize=”true” showPrice=”true” showImage=”true”] Rdi, Antibodies, Elisa kits

Compare recombinant lab reagents for research

Suppliers for Lab reagents [Linking template=”default” search=”plant” site=”gentaur.it” header=”h2″ limit=”7″ start=”12″ linkProductCatalogNumber=”true” showSupplier=”true” showName=”true” showCatalogNumber=”true” showSize=”true” showDescription=”true”] [Linking template=”default” search=”TEST” site=”gentaur.co.uk” header=”h2″ limit=”8″ linkProductSupplierName=”true” showSupplier=”true” showName=”true” showCatalogNumber=”true” showSize=”true” showPrice=”true” showImage=”true”] Our used recombinants in Pubmed. [Linking template=”default” search=”polyclonal” header=”h3″ start=”20″ limit=”5″ linkProductSupplierName=”true” showSupplier=”true” showName=”true” showCatalogNumber=”true” showSize=”true” showPrice=”true” showImage=”true”]

Isolation of exosome from the culture medium of Nasopharyngeal cancer (NPC) C666-1 cells using inertial based Microfluidic channel

Isolation of exosome from culture medium in an effective way is desired for a less time consuming, cost saving technology in running the diagnostic test on cancer. In this study, we aim to develop an inertial microfluidic channel to separate the nano-size exosome from C666-1 cell culture medium as a selective sample. Simulation was carried out to obtain the optimum flow rate for determining the dimension of the channels for the exosome separation from the medium.
The optimal dimension was then brought forward for the actual microfluidic channel fabrication, which consisted of the stages of mask printing, SU8 mould fabrication and ended with PDMS microchannel curing process. The prototype was then used to verify the optimum flow rate with polystyrene particles for its capabilities in the actual task on particle separation as a control outcome. Next, the microchip was employed to separate the selected samples, exosome from the culture medium and compared the outcome from the conventional exosome extraction kit to study the level of effectiveness of the prototype.
The exosome outcome from both the prototype and extraction kits were characterized through zetasizer, western blot and Transmission electron microscopy (TEM). The microfluidic chip designed in this study obtained a successful separation of exosomes from the culture medium. Besides, the extra benefit from these microfluidic channels in particle separation brought an evenly distributed exosome upon collection https://joplink.net/exosome-isolation-kits/ while the exosomes separated through the extraction kit was found clustered together. Therefore, this work has shown the microfluidic channel is suitable for continuous separation of exosomes from the culture medium for a clinical study in the future.

Characterization of surface markers on extracellular vesicles isolated from lymphatic exudate from patients with breast cancer

Background: Breast cancer is the most common cancer, and the leading cause of cancer-related deaths, among females world-wide. Recent research suggests that extracellular vesicles (EVs) play a major role in the development of breast cancer metastasis. Axillary lymph node dissection (ALND) is a procedure in patients with known lymph node metastases, and after surgery large amounts of serous fluid are produced from the axilla. The overall aim was to isolate and characterize EVs from axillary serous fluid, and more specifically to determine if potential breast cancer biomarkers could be identified.
Methods: Lymphatic drain fluid was collected from 7 patients with breast cancer the day after ALND. EVs were isolated using size exclusion chromatography, quantified and detected by nanoparticle tracking analysis, electron microscopy, nano flow cytometry and western blot. The expression of 37 EV surface proteins was evaluated by flow cytometry using the MACSPlex Exosome kit.
Results: Lymphatic drainage exudate retrieved after surgery from all 7 patients contained EVs. The isolated EVs were positive for the typical EV markers CD9, CD63, CD81 and Flotillin-1 while albumin was absent, indicating low contamination from blood proteins. In total, 24 different EV surface proteins were detected.
Eleven of those proteins were detected in all patients, including the common EV markers CD9, CD63 and CD81, cancer-related markers CD24, CD29, CD44 and CD146, platelet markers CD41b, CD42a and CD62p as well as HLA-DR/DP/DQ. Furthermore, CD29 and CD146 were enriched in Her2+ patients compared to patients with Her2- tumors.
Conclusions: Lymphatic drainage exudate retrieved from breast cancer patients after surgery contains EVs that can be isolated using SEC isolation. The EVs have several cancer-related markers including CD24, CD29, CD44 and CD146, proteins of potential interest as biomarkers as well as to increase the understanding of the mechanisms of cancer biology.

Understanding the Role and Clinical Applications of Exosomes in Gynecologic Malignancies: A Review of the Current Literature

Background: Gynecologic malignancies are those which arise in the female reproductive organs of the ovaries, cervix, and uterus. They carry a great deal of morbidity and mortality for patients, largely due to challenges in diagnosis and treatment of these cancers. Although advances in technology and understanding of these diseases have greatly improved diagnosis, treatment, and ultimately survival for patients with gynecologic malignancies over the last few decades, there is still room for improvements in diagnosis and treatment, for which exosomes may be the key. This paper reviews the current knowledge regarding gynecologic tumor derived-exosomal genetic material and proteins, their role in cancer progression, and their potential for advancing the clinical care of patients with gynecologic cancers through novel diagnostics and therapeutics.
Literature review: Ovarian tumor derived exosome specific proteins are reviewed in detail, discussing their role in ovarian cancer metastasis. The key microRNAs in cervical cancer and their implications in future clinical use are discussed. Additionally, uterine cancer-associated fibroblast (CAF)-derived exosomes which may promote endometrial cancer cell migration and invasion through a specific miR-148b are reviewed. The various laboratory techniques and commercial kits for the isolation of exosomes to allow for their clinical utilization are described as well.
Conclusion: Exosomes may be the key to solving many unanswered questions, and closing the gaps so as to improve the outcomes of patients with gynecologic cancers around the world. The potential utilization of the current knowledge of exosomes, as they relate to gynecologic cancers, to advance the field and bridge the gaps in diagnostics and therapeutics highlight the promising future of exosomes in gynecologic malignancies.

Pathogenic Mechanisms of Preeclampsia with Severe Features Implied by the Plasma Exosomal miRNA Profile

Preeclampsia is a complication of pregnancy characterised by high blood pressure and organ damage after 20 gestational weeks. It is associated with high maternal and fetal morbidity and mortality; however, at present, there is no effective prevention or treatment for this condition. Previous studies have revealed that plasma exosomal miRNAs from pregnant women with preeclampsia could serve as biomarkers of pathogenic factors. However, the roles of plasma exosomal miRNAs in preeclampsia with severe features (sPE), which is associated with poorer pregnancy outcomes, remain unknown.
Thus, the aims of this study were to characterise plasma exosomal miRNAs in sPE and explore the related pathogenic mechanisms using bioinformatic analysis. Plasma exosomes were isolated using a mirVana RNA isolation kit.
The exosomal miRNAs were detected using high-throughput sequencing and the miRNAs related to Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways and gene ontology (GO) terms were analysed using the clusterProfiler package of R. Fifteen miRNAs exhibited increased expression and fourteen miRNAs exhibited reduced expression in plasma exosomes from women with sPE as compared to normal pregnant women.
Further, gene set enrichment analysis revealed that the differentially expressed plasma exosomal miRNAs were related to the stress response and cell junction regulation, among others. In summary, this study is the first to identify the differentially expressed plasma exosomal miRNAs in sPE. These findings highlight promising pathogenesis mechanisms underlying preeclampsia.

[Linking template=”default” search=”Exosome Isolation Kit for Cell Culture” header=”h2″ classTable=”ADAM Clone 21″ limit=”10″ start=”0″ linkProductName=”true” showName=”true” showSize=”true” showPrice=”true” ]

GenMark ePlex NATtrol

In March, GenMark received EUA for its ePlex SARS-CoV-2 Test. Respiratory Pathogen Panel. Multiplex molecular diagnostic solutions provider GenMark Diagnostics has secured CE mark approval for its ePlex respiratory pathogen panel 2 (RP2). The ePlex RP has received FDA clearance for nasopharyngeal swab (NPS) specimens collected in viral transport media. COVID-19. ;

The RP2 Panel provides results in less than two hours for more than 20 viruses and bacteria that cause common respiratory infections with similar symptoms, including COVID-19, flu, bronchitis, and the common cold. Clinical implications of rapid eplex® respiratory pathogen panel testing compared to laboratory-developed real-time PCR Anneloes L. van Rijn, Roel H.T. Due to the batch-wise testing, laboratory-developed real-time polymerase chain reaction (PCR) assays (LDT) often result in a time to result of one day.

10/01/2019: Under Article Text added the third bullet point verbiage “For dates of service on or after 10/1/2019, laboratories billing for services using GenMark” ePlex Respiratory Pathogen (RP) Panel should report 0115U. The ePlex RP2 Control M451 is composed of synthetic DNA and RNA specifically designed for and intended to be used solely with the ePlex RP2 Panel on the ePlex System. In March, GenMark received EUA for its ePlex SARS-CoV-2 Test. Read More.

The ePlex respiratory pathogen panel (RP panel) is a novel molecular biology-based assay, developed by GenMark Diagnostics, Inc. (Carlsbad, CA), to be performed within a single cartridge for the diagnosis of 25 respiratory pathogens (viral and bacterial). in Top News. GenMarkâs ePLex-BCID Gram-Positive panel detects 20 bacterial targets, and the Fungal Pathogen panel detects 13 yeast pathogens in one and a half hours. AB Molecular Ltd. Butyl Road, Botolph Claydon, Respiratory Pathogen Panel. AB Molecular is the exclusive distributor in the UK for GenMark Dx and has been established to promote their innovative ePlex technology.

The ePlex RP2 Panel is designed for use with the companyâs ePlex system, which has been cleared by the FDA for use with the ePlex Respiratory Pathogen (RP) Panel and Blood Culture Identification (BCID) Panels (Gram-positive, Gram-negative and Fungal pathogens). The QIAstat-Dx® RP assay detected 312 of the 338 respiratory targets (92%) that were detected by the ePlex® RPP assay. This assay does NOT detect SARS CoV-2 (novel coronavirus) or MERS. Multiplex molecular panels provide high sensitivity (few false negatives) and specificity (few false positives) for multiple pathogens in ⦠GenMarkâs ePlex Respiratory Pathogen Panel 2 (RP2) achieves CE mark.

The company said RP2 drove the majority of the placements and revenues in Q3. Respiratory Panel 2 (RP2)] 0115U Respiratory infectious agent detection by nucleic acid (DNA and RNA), 18 viral types and subtypes and 2 bacterial targets, amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected [USE FOR GenMark ePlex Respiratory Pathogen (RP) Panel] SARS-CoV-2 (2 assays) Seasonal coronavirus.

We are very pleased to announce the 510(k) clearance of ePlex and the Respiratory Pathogen Panel. The new RP2 panel includes SARS-CoV-2, the pathogen that causes COVID-19. If the tube system is used, ensure specimens are in leak-proof containers that are securely closed and double bagged. ORIGINAL ARTICLE Clinical implications of rapid ePlex® Respiratory Pathogen Panel testing compared to laboratory-developed real-time PCR Anneloes L. van Rijn1 & Roel H. T. Nijhuis1 & Vincent Bekker 2 & Geert H.

Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force.

Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force.

A Task Force was commissioned collectively by the European Academy of Allergy and Clinical Immunology (EAACI) and the Respiratory Effectiveness Group (REG) to develop a high quality evaluation device for real-life observational analysis to establish high-quality real-life bronchial asthma research that might be thought-about inside future guideline growth.The ensuing REal Life EVidence AssessmeNt Tool (RELEVANT) was achieved by way of an intensive evaluation of present initiatives in this space.

The first model was piloted amongst 9 raters throughout 6 articles; the revised, interim, model underwent in depth testing by 22 reviewers from the EAACI membership and REG collaborator group, resulting in additional revisions and device finalisation. RELEVANT was validated by way of an evaluation of real-life effectiveness research recognized by way of systematic evaluate of Medline and Embase databases and regarding subjects for which real-life research might provide priceless proof complementary to that from randomised managed trials.

The subjects have been chosen by way of a vote amongst Task Force members and associated to the affect of adherence, smoking, inhaler machine and particle measurement on bronchial asthma remedy effectiveness.Although highlighting a basic lack of high-quality real-life effectiveness observational analysis on these clinically vital subjects, the evaluation offered insights into how recognized observational research may inform bronchial asthma pointers builders and clinicians.

Overall, RELEVANT appeared dependable and straightforward to make use of by professional reviewers.Using such high quality appraisal instruments is obligatory to evaluate whether or not particular observational real-life effectiveness research can be utilized to tell guideline growth and/or decision-making in medical observe.

 Quality standards in respiratory real-life effectiveness research: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force.
Quality standards in respiratory real-life effectiveness analysis: the REal Life EVidence AssessmeNt Tool (RELEVANT): report from the Respiratory Effectiveness Group-European Academy of Allergy and Clinical Immunology Task Force.

New European Academy of Allergy and Clinical Immunology definition on pollen season mirrors symptom load for grass and birch pollen-induced allergic rhinitis.

BACKGROUND
The use of allergen immunotherapy (AIT) for allergic rhinitis and its medical efficacy in medical trials will depend on the efficient dedication of pollen allergen publicity time durations. We consider pollen information from Germany to look at the new definitions on pollen season and peak pollen interval begin and finish as proposed by the European Academy of Allergy and Clinical Immunology (EAACI) in a just lately printed Position Paper. The goal was to reveal the potential of these definitions to reflect symptom hundreds for grass and birch pollen-induced allergic rhinitis primarily based on real-life information.
[Linking template=”default” type=”products” search=”FBXW7″ header=”2″ limit=”165″ start=”1″ showCatalogNumber=”true” showSize=”true” showSupplier=”true” showPrice=”true” showDescription=”true” showAdditionalInformation=”true” showImage=”true” showSchemaMarkup=”true” imageWidth=”” imageHeight=””]
METHODS
Data coming from 4 pollen monitoring stations in the Berlin and Brandenburg space in Germany and for three years (2014-2016) have been used to analyze the correlation of season definitions, birch and grass pollen counts and complete nasal symptom and mediation scores as reported by sufferers in “Patients Hay fever Diaries” (PHDs). After the identification of pollen durations on the foundation of the EACCI standards, a statistical evaluation was employed, adopted by an in depth graphical investigation.
RESULTS
The evaluation revealed that the definitions of pollen season in addition to peak pollen interval begin and finish as proposed by the EAACI are correlated to symptom hundreds for grass and birch pollen-induced allergic rhinitis reported by sufferers in PHDs.
CONCLUSIONS
Based on our evaluation, the validity of the EAACI definitions on pollen season is confirmed. Their use is advisable in future medical trials on AIT in addition to in each day routine for optimum affected person care.

Antigens

Antigens are defined as substances capable of stimulating the production of antibodies, with which they react specifically. This definition is incomplete since it is well known that antigens can induce cell-mediated immune responses. So antigens are all molecules introduced into the body that can induce an immune response; that is to say the induction of the production of specific immune effectors (humoral or cellular) and to react with these.

antigen is a category of molecules (a molecular species) defined by its antigenic specificity. And, it defines antigenic specificity as the property of a given antigen to combine with a given (usually heterogeneous) population of antibodies. A given antigen can combine with several different or identical antibodies.

Classifications

According to origin

– Xeno-antigen XENO ANTIGENS: these are the antigens present in all individuals of one or more species distinct from that to which the immunized subject belongs.
– Allo antigens (Iso antigens): these are antigens found in a group of individuals of the same species and can induce an immune response in individuals who do not have them.
– Auto antigens: these are the antigens of an individual that can induce an anti-self immune response.

Depending on whether the production of antibodies depends on T cells or not

– Thymo-dependent antigens: are those against which the production of antibodies requires the help of T lymphocytes. This category is mainly represented by proteins.
– Thymo independent antigens: are those against which the production of antibodies does not require the help of T lymphocytes; such as polysaccharides and lipopolysacharides which are characterized by the presence of repetitive epitopes.

According to the chemical nature

 Protein antigens: these are the most immunogenic antigens. There are several types:
– Natural proteins: these are the main constituents of living things. They are encoded by corresponding genes.
– Artificial proteins: these are proteins whose natural core is on which side sequences are grafted.
– Synthetic proteins.

 Polysaccharide antigens: the immunogenic power of these antigens is weak. The simple polysaccharides have repetitive antigenic determinants which can activate B lymphocytes without resorting to T lymphocytes. The antigenic determinants of these antigens are sequential and nonconformational determinants, of approximately 6 sugars.

 Lipid antigens: lipids are not immunogenic. however, after their association with proteins, they can induce an immune response. They play the role of haptens. In certain diseases we find anti phospholipid antibodies.

 Nucleic acids: the immunogenicity of these substances is controversial when all attempts at immunization fail. However, immunization with nucleic acids associated with proteins induces the production of specific antibodies.

According to physical properties (solubility)

 Soluble antigens: constitute the majority of antigens in nature (proteins, polysaccharides, etc.)
 Particulate antigens: correspond to all particles, living or inert, which can induce an immune response (bacteria, virus, cell, parasite, etc.)

Applications

  1. vaccination
  2. serotherapy
  3. in vitro diagnosis
  4. skin tests
  5. desensitization